copiktra
(duvelisib)Secura Bio, Inc.
Usage: COPIKTRA is indicated for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have undergone at least two prior therapies.
10 results
cyclophosphamide
(cyclophosphamide)Baxter Healthcare CorporationUsage: Cyclophosphamide for Injection is indicated for treating various malignancies in adults and pediatric patients, including malignant lymphomas, multiple myeloma, leukemias, and specific cancers like breast and ovarian carcinoma. It's also used for pediatric minimal change nephrotic syndrome when corticosteroid therapy fails.cyclophosphamide
(Cyclophosphamide)Amneal Pharmaceuticals LLCUsage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, several types of leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids.cyclophosphamide
(cyclophosphamide)Bamboo US Bidco LCCUsage: Cyclophosphamide is indicated for treating various malignant diseases, including lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids. Safety in adults for this condition is not established.cyclophosphamide - cyclophosphamide injection, powder, for solution
(Cyclophosphamide)Northstar RxllcUsage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including lymphomas, multiple myeloma, leukemias, and certain carcinomas. It is also used for pediatric patients with biopsy-proven minimal change nephrotic syndrome who do not respond to corticosteroids. Safety in adults is not established for nephrotic syndrome.gazyva
(obinutuzumab)Genentech, Inc.Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.imbruvica
(Ibrutinib)Pharmacyclics LLCUsage: IMBRUVICA is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia, and for treating chronic graft-versus-host disease in patients aged 1 year and older after failure of prior systemic therapy.rituxan hycela
(rituximab and hyaluronidase)Genentech, Inc.Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.venclexta
(Venetoclax)AbbVie Inc.Usage: VENCLEXTA is indicated for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also used in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) in adults aged 75 or older, or with significant comorbidities.zydelig
(idelalisib)Gilead Sciences, Inc.Usage: Zydelig is indicated, in combination with rituximab, for treating relapsed chronic lymphocytic leukemia (CLL) in patients for whom rituximab alone is appropriate due to co-morbidities. It is not recommended for first-line treatment or with specific combinations for other lymphomas.